| Hazard ratio | 95% confidence interval |
---|
DFS |
   All patients | 0.63 | 0.47 to 0.83 |
   N1 to N3 | 0.64 | 0.42 to 0.97 |
   N4+
| 0.59 | 0.38 to 0.91 |
SysDFS |
   All patients | 0.66 | 0.49 to 0.88 |
   N1 to N3 | 0.68 | 0.45 to 1.04 |
   N4+
| 0.63 | 0.41 to 0.97 |
Overall survival |
   All patients | 0.73 | 0.55 to 0.98 |
   N1 to N3 | 0.76 | 0.50 to 1.15 |
   N4+
| 0.63 | 0.41 to 0.97 |
- Cyclophosphamide methotrexate, 5-fluoracil + radiation versus cyclophosphamide methotrexate, 5-fluoracil alone, including all patients and involving patients with one to three axillary nodes involved (N1 to N3) and patients with four or more axillary nodes involved (N4+). DFS, first event breast cancer recurrence (or any death); SysDFS, DFS with systemic recurrence as a first event. Adapted from Ragaz and colleagues [12].